A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
Read more: CRISPR Used to Repair Blindness-causing Genetic Defect in Patient-derived Stem Cells
The Latest on: Retinitis pigmentosa
[google_news title=”” keyword=”retinitis pigmentosa” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Retinitis pigmentosa
- Audio library 'Hidden Voices' turns five this Aprilon April 27, 2024 at 4:30 pm
A chance meeting can often change the course of a life. Kochi psychotherapist Devi Krishna meeting Sudheesh, a visually-challenged teacher, in 2019 was one of those, and a happy one at that. Sudheesh ...
- Nanoscope Therapeutics Appoints New Chief Medical Officeron April 26, 2024 at 3:38 pm
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye ...
- ‘Death penalty and justice’: Dover murder victim’s sister wants suspect executedon April 26, 2024 at 10:59 am
The family of a woman and a 4-year-old who were murdered in Dover says they want the man arrested in their deaths to be executed.
- ‘He had so much potential’: Boy accidentally shot, killed by sibling at St. Pete home with stolen gun, police sayon April 26, 2024 at 10:15 am
An 11-year-old boy has died after suffering life-threatening injuries when he was shot on Friday in St. Petersburg, according to officials.
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meetingon April 26, 2024 at 6:04 am
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that ...
- Solar panels in the eyes: reality or distant future?on April 26, 2024 at 4:44 am
Implanting tiny solar cells in people's eyes might sound like a futuristic idea, but it's what Australian scientists are exploring. This advanced technology could greatly help those with eye diseases.
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meetingon April 26, 2024 at 3:34 am
Title: Nuclear Hormone Receptor RORA as a Novel Modifier Approach for Treatment of Stargardt Disease Presenter: Murthy Chavali, PhD, Director, Clinical Development, Ocugen Location: Show Floor, ...
- BCI maker Science acquires retinal implant from Pixium Visionon April 25, 2024 at 12:54 pm
Brain-computer interface developer Science Corporation acquired the IP and related assets for the Pixium Vision Prima implant.
- Restoring sight is possible now with optogeneticson April 23, 2024 at 3:30 am
Several companies are experimenting with optogenetics to create a “bionic eye” that can restore sight in visually impaired people.
- Driverless Vehicle Technology Redefines Travel For A Blind World Championship Roweron April 22, 2024 at 1:58 pm
Pearl’s condition, called Retinitis Pigmentosa, prevents her from owning a driver’s license – limiting her ability to travel around or outside her home town, due to ...
via Bing News